Barclays PLC Has $660,000 Stock Holdings in Cryoport, Inc. (NASDAQ:CYRX)

Barclays PLC grew its stake in Cryoport, Inc. (NASDAQ:CYRX) by 272.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,417 shares of the company’s stock after acquiring an additional 59,582 shares during the period. Barclays PLC owned 0.16% of Cryoport worth $660,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Geode Capital Management LLC boosted its position in Cryoport by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company’s stock valued at $8,902,000 after purchasing an additional 38,520 shares during the last quarter. Bullseye Asset Management LLC grew its stake in shares of Cryoport by 58.7% in the third quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company’s stock valued at $1,737,000 after buying an additional 79,244 shares in the last quarter. State Street Corp increased its holdings in Cryoport by 2.8% during the third quarter. State Street Corp now owns 1,003,080 shares of the company’s stock worth $8,135,000 after buying an additional 27,438 shares during the last quarter. Stifel Financial Corp raised its position in Cryoport by 11.0% during the third quarter. Stifel Financial Corp now owns 139,745 shares of the company’s stock worth $1,133,000 after acquiring an additional 13,809 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in Cryoport in the third quarter valued at $3,405,000. Institutional investors own 92.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CYRX. UBS Group upped their target price on shares of Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a report on Friday, October 18th. Guggenheim began coverage on Cryoport in a research note on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective on the stock. Finally, Roth Mkm reduced their target price on Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Cryoport presently has a consensus rating of “Moderate Buy” and an average price target of $12.29.

Insider Activity at Cryoport

In other Cryoport news, CEO Jerrell Shelton sold 50,000 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $6.78, for a total value of $339,000.00. Following the completion of the sale, the chief executive officer now owns 712,747 shares of the company’s stock, valued at $4,832,424.66. The trade was a 6.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the transaction, the director now directly owns 59,497 shares in the company, valued at $443,847.62. This represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,869 shares of company stock worth $735,673 in the last ninety days. 10.10% of the stock is owned by company insiders.

Cryoport Trading Up 1.9 %

Shares of NASDAQ:CYRX opened at $7.49 on Friday. The stock has a market cap of $370.23 million, a PE ratio of -2.22 and a beta of 1.58. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a 12-month low of $5.32 and a 12-month high of $20.10. The business has a 50 day moving average of $7.69 and a 200-day moving average of $7.85.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.